TOULARYNX DEXTROMETHORPHAN FORTE 3 mg/ml, syrup Dextromethorphan HBr monohydrate

Similar documents
Benylin Children's Coughs & Colds 5mg/0.625mg per 5ml Syrup dextromethorphan, triprolidine

Package leaflet: Information for the user. Omnilax 10 g powder for oral solution, sachet. Macrogol 4000

Package leaflet: Information for the patient

Package Leaflet: INFORMATION FOR THE USER. PARACODIN 10 mg/g oral drops, solution (dihydrocodeine hydrorhodanide)

Zofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

PACKAGE LEAFLET: INFORMATION FOR THE USER. ZADITEN 1 mg/5 ml Oral Solution. Ketotifen (as Ketotifen hydrogen fumarate)

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride

Zofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

Package leaflet: Information for the patient

Package leaflet: Information for the user. Ondansetron 4mg/5ml Syrup (ondansetron as ondansetron hydrochloride dihydrate)

Package leaflet: Information for the user

Imodium 1 mg/5 ml oral solution

PACKAGE LEAFLET: INFORMATION FOR THE USER. Aspecton Cough Syrup. Thyme soft extract. For adults and children aged 1 year and older

Package leaflet: Information for the User Clarityn 1 mg/ml syrup Loratadine

PACKAGE LEAFLET: INFORMATION FOR THE USER Paracodin 0.20% w/w Syrup (dihydrocodeine hydrogen tartrate)

FLUIMUKAN PLUS 600 mg effervescent tablets

PACKAGE LEAFLET. Page 1

Package leaflet: Information for the user. <PRODUCT NAME> 10 g powder for oral solution in sachet Macrogol 4000

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER ZIRPINE 10mg TABLETS Cetirizine dihydrochloride

Flavamed Forte 30 mg/5 ml, oral solution

Package leaflet: Information for the patient

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. ILAXTEN 20 MG TABLETS bilastine

SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for users. Imodium 2 mg orodispersible tablets Loperamide hydrochloride

Package leaflet: Information for the user. Zidoval 7.5 mg/g Vaginal Gel Metronidazole

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

PACKAGE LEAFLET. Page 1 of 6

Package leaflet: Information for the patient. Bumetanide 1 mg and 5 mg Tablets (bumetanide)

Package leaflet: Information for the user. Tetrabenazine 25 mg tablets. tetrabenazine

Package Leaflet: Information for the User

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT

Package leaflet: Information for the User Clarityn 10 mg tablets Loratadine

Package leaflet: Information for the patient. Loratadine 10 mg Tablets (loratadine)

Package leaflet: Information for the patient. Dexametason Abcur 4 mg tablets. Dexamethasone

Package leaflet: Information for the user. Acetylcysteine Sanofi 600 mg bruistabletten Acetylcysteine

Package leaflet: Information for the patient. Vertigon 8 mg Tablets Vertigon 16 mg Tablets (betahistine dihydrochloride)

Package leaflet: Information for the user. Nocdurna 25 microgram oral lyophilisate Nocdurna 50 microgram oral lyophilisate.

Package leaflet: Information for the patient. For children from two years, adolescents and adults Ambroxol hydrochloride

Package Leaflet: Information for the user Kemadrin 5 mg Tablets Procyclidine hydrochloride

Package leaflet: Information for the user. Ebateva 20 mg Orodispersible Tablets. Ebastine

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium

Package leaflet: Information for the patient. Chlorphenamine 10 mg/ml Solution for Injection (Chlorphenamine Maleate)

Package leaflet: Information for the user

Zofran tablets contain a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

Package leaflet: Information for the patient. Bromhexin Krewel Meuselbach Drops 12 mg/ml. Bromhexine hydrochloride

Patient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol

Hedelix Cough Effervescent Tablets are used to relieve symptoms of chronic inflammatory bronchial conditions; for colds affecting the airways.

1. What Betahistine dihydrochloride tablets is and what it is used for

Package Leaflet: Information for the user. Methocarbamol 750mg Film-Coated Tablets

Package Leaflet: Information for the User Zofran tablets 4 mg and 8 mg ondansetron (as hydrochloride dihydrate)

Package Leaflet: Information for the User

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride

Package leaflet: Information for the user. Morfin Abcur 10 mg/ml, solution for injection. morphine hydrochloride

PATIENT INFORMATION LEAFLET. Active substances: Each 5 ml syrup (1 spoon) contains 2.5 mg desloratadine.

Package leaflet: Information for the user. Colecalciferol 3000 IU/ml Oral Solution (colecalciferol)

PACKAGE LEAFLET: INFORMATION FOR THE USER

1. What Octostim Nasal Spray is and what it is used for

PATIENT INFORMATION LEAFLET

1 What Zofran Suppositories are and what they are used for

1 What Zofran Zydis is and what it is used for

What does this PIL contain?

Package Leaflet: Information for the User. Glucosamine sulfate 750 mg Film-Coated Tablets

Package leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

Package leaflet: Information for the patient. Velphoro 500 mg chewable tablets Iron as sucroferric oxyhydroxide

Package leaflet: Information for the user. Nicotinell Tropisk frukt 4 mg medicated chewing-gum

Package leaflet: Information for the user Cyklokapron 500 mg Solution for Injection tranexamic acid

Package leaflet: Information for the patient. Calcium Folinate 15 mg Tablets calcium folinate

Package leaflet: Information for the user. Burinex 5 mg Tablets bumetanide

Package leaflet: Information for the patient. Torarese 2.5 mg tablets Torarese 5 mg tablets Torarese 10 mg tablets Torarese 20 mg tablets.

Package Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron

Package leaflet: Information for the user Zirtek Allergy Relief for Children 1 mg/ml Oral Solution Cetirizine dihydrochloride

2 What you need to know before you use Zofran Suppositories

Package leaflet: Information for the patient LOCABIOTAL Pressurised 125 micrograms Nasal/Oromucosal spray solution Fusafungine

HERNOVIR 200 mg tablets

Irbenida H 150mg/12,5mg film-coated tablets

Package leaflet: Information for the user. Raxone 150 mg film-coated tablets idebenone

LYSOBACT COMPLETE SPRAY ( ) mg / ml Oromucosal spray, solution

PACKAGE LEAFLET: INFORMATION FOR THE USER. <PRODUCT NAME> 600 mg / 1,000 IU orodispersible tablets. Calcium/cholecalciferol (Vitamin D3)

Package leaflet: Information for the patient. Megalac Almasilate 1 g/10 ml suspension. Active substance: almasilate

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. Tardiben 25 mg tablets. Tetrabenazine

Package leaflet: Information for the user. Tianeptine 12.5 mg Film Coated Tablets (Tianeptine Sodium)

1. WHAT OXCARBAZEPINE IS AND WHAT IT IS USED FOR

Package leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. Calcichew-D 3 Melon 500 mg/1000 IU chewable tablets calcium/cholecalciferol (vitamin D 3 )

Aciclovir Apotex 800 mg tabletten RVG Package leaflet: Information for the user Aciclovir Apotex 800 mg tabletten Aciclovir

PACKAGE LEAFLET: INFORMATION FOR THE USER Insomniger 10mg and 20mg Tablets (temazepam)

Package leaflet: Information for the patient. Pikopil druppels voor oraal gebruik, oplossing, 7.5 mg/ml. Sodium picosulfate

FLUIMUKAN AKUT 600 mg effervescent tablets

Package leaflet: Information for the patient. Brimonidine Biogaran 2 mg/ml eye drops, solution. brimonidine tartrate

Package leaflet: Information for the patient

Package leaflet: Information for the user. Flutamid Stada 250 mg tablets Flutamide

SPASMEX FORTE 5mg tablets

Sanomigran 500 microgram Tablets and Sanomigran 1.5 mg Tablets

Transcription:

TOULARYNX DEXTROMETHORPHAN FORTE 3 mg/ml, syrup Dextromethorphan HBr monohydrate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Toularynx dextromethorphan forte is and what it is used for. 2. What you need to know before you take Toularynx dextromethorphan forte. 3. How to take Toularynx dextromethorphan forte. 4. Possible side effects. 5. How to store Toularynx dextromethorphan forte. 6. Contents of the pack and other information. 1. WHAT TOULARYNX DEXTROMETHORPHAN FORTE IS AND WHAT IT IS USED FOR. Toularynx dextromethorphan forte belongs to the group of cough inhibitors. Toularynx dextromethorphan forte is recommended for the treatment of the symptoms of an annoying, dry cough. Toularynx dextromethorphan forte is recommended for adults and children from 6 years old. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE TOULARYNX DEXTROMETHORPHAN FORTE. Do not take Toularynx dextromethorphan forte - If you are allergic to dextromethorphan hydrobromide or any of the other ingredients of this medicine (listed in section 6). - In case of severe respiratory complaints. - In children younger than 6 years old. - If you already use certain medicines against depression (inhibitors of Monoamine Oxidase) or within 14 days after treatment with these medicines. Please also read the section: Other medicines and Toularynx dextromethorphan forte. - When breast-feeding. Please also read the section: Pregnancy, breast-feeding and fertility Warnings and precautions Talk to your doctor or pharmacist before taking Toularynx dextromethorphan forte. 1/6

- Cough with expectorations is an import defense mechanism of the respiratory tract. Cough inhibitors are not recommended in this case. - The administration of a cough inhibitor together with a mean to facilitate the coughing up of mucus (expectorant) or a mean to dissolve mucus (mucolytic) is not useful. - Before using a cough inhibitor, one needs to make sure that the causes of cough that need a specific treatment, are examined. - Consult your doctor if the cough persists after 4 to 5 days. - Caution should be exercised in the elderly, in people with hepatic or renal impairment and people with asthma, bronchitis or emphysema (a certain lung disease, characterized by a reduced elasticity of the lungs, causing shortness of breath). - The intake of alcohol is not recommended during the treatment. Please also read the section: Toularynx dextromethorphan forte with food, drink and alcohol. - Because of the variability in a certain gene (the CYP2D6 allele) in the population, a limited impact is possible on side effects or the lack of effect of the medicine when using the standard dose. - Toularynx dextromethorphan forte causes no physical dependence when using a normal dose. Prolonged use of high doses may however cause dependence. - When using other medicines. Please also read the section: Other medicines and Toularynx dextromethorphan forte. Consult your doctor if one of the above warnings applies to you, or if this has been the case in the past. Children Do not administer this medicine to children under 6 years of age. Other medicines and Toularynx dextromethorphan forte Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. - Under no circumstances, Toularynx dextromethorphan forte may be taken together with certain medicines against depression (inhibitors of Monoamine Oxidase) or within 14 days after treatment with these medicines because of the possible risk of serotonin syndrome. - There is a possibility of interaction with certain medicines that inhibit the CYP2D6 enzyme: - Certain medicines against depression (selective serotonin reuptake inhibitors or SSRI s like fluoxetine, paroxetine) - Certain medicines against arrhythmias (amiodarone, quinidine, propafenone) - Certain medicines against psychosis (haloperidol, thioridazine) Toularynx dextromethorphan forte with food, drink and alcohol Simultaneous use of alcohol is not recommended: this combination may lead to an enhancement of the sedative effect. Simultaneous use of grapefruit juice and bitter orange juice is not recommended because this may increase the bioavailability of dextromethorphan. Pregnancy, breast-feeding and fertility 2/6

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy There is no information available about the transfer of dextromethorphan through the placenta. As a precaution, the use of Toularynx dextromethorphan forte should be avoided during the first three and the last three months of the pregnancy. Breast-feeding The use of Toularynx dextromethorphan forte in the breast-feeding period should be avoided since it can bring about depressed breathing in the new-born baby. Fertility There are no relevant fertility data available. Driving and using machines Persons who drive motor vehicles or operate machines should keep in mind that a high dose can decrease alertness. The use of alcohol can intensify this effect. Toularynx dextromethorphan forte contains sorbitol, methyl parahydroxybenzoate, propyl parahydroxybenzoate and alcohol Toularynx dextromethorphan forte contains sorbitol. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. Sorbitol may have a mild laxative effect. The calorific value is 2,6 kcal/g sorbitol. Toularynx dextromethorphan forte also contains methyl parahydroxybenzoate and propyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed). Toularynx dextromethorphan forte contains small amounts of alcohol (ethanol), less than 100 mg per dose. 3. HOW TO TAKE TOULARYNX DEXTROMETHORPHAN FORTE. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The packaging contains a cup that can measure up to 30 ml. The bottle is sealed with a child-resistant closure that should be opened as followed: push the closure down while turning counter-clockwise (see figure). The recommended dose is: Adults: 10 ml, maximum 4 times a day. In elderly and in people with hepatic or renal impairment the dose should be reduced by half. Toularynx dextromethorphan forte may be used by diabetics. 3/6

Treatment with Toularynx dextromethorphan forte aims to suppress the symptoms; the use should be restricted to the lowest dose possible over as short a period as possible. Use in children and adolescents Children over 12 years of age: 10 ml, maximum 4 times a day. Children from 6 to 12 years: 5 ml, maximum 4 times a day. Do not administer to children under 6 years of age. Treatment with Toularynx dextromethorphan forte aims to suppress the symptoms; the use should be restricted to the lowest dose possible over as short a period as possible. If you take more Toularynx dextromethorphan forte than you should If you have taken too much Toularynx dextromethorphan forte, contact your doctor, your pharmacist or the Anti-Poison centre (070/245.245) immediately. The possibility exists that too much medicine is taken by accident, especially by children. If a patient is suspected of having taken an overdose, he or she should be kept under careful observation, and if necessary, hospitalized. The following are signs of overdosing: nausea, vomiting, constipation, decreased vision, involuntary eye movements (nystagmus), dilated pupils (mydriasis), drowsiness, dizziness, incoordination (ataxia), disorders of muscle tone (dystonia), decreased consciousness, psychosis, hallucinations, convulsions, agitation, increased heartbeat, increased blood pressure, breathing difficulties and coma. Overdosing may also cause bromide poisoning. The antidote is naloxone. If you forget to take Toularynx dextromethorphan forte Do not take a double dose to make up for a forgotten dose. If you stop taking Toularynx dextromethorphan forte There are no specific problems to be expected when the treatment is stopped. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. POSSIBLE SIDE EFFECTS. Like all medicines, Toularynx dextromethorphan forte can cause side effects, although not everybody gets them. Side effects are classified according to organ system with evaluation of the frequency according to the following convention: very common ( 1/10), common ( 1/100, < 1/10), uncommon ( 1/1000, < 1/100), rare ( 1/10000, < 1/1000), very rare (< 1/10000), not known (cannot be estimated from the available data). The following severe side effects may occur: Immune system (frequency not known): Anaphylactic shock (a severe allergic reaction), hypersensitivity reactions like rash, itching, hives, swelling (angio-oedema) and cramping of the muscles around the trachea (bronchospasms). In any of these cases you should stop the treatment and immediately contact your doctor or pharmacist. 4/6

The following side effects may occur as well: Nervous system (frequency not known): Dizziness, confusion, headache, excitation, drowsiness. Respiratory system (frequency not known): Dextromethorphan has at normal dosage no effect on the respiration. At very high dose the respiration may however be suppressed. Gastrointestinal system (frequency not known): Constipation, nausea, stomach ache, decreased appetite. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Federal Agency for Medicines and Health Products, Department Vigilance, EUROSTATION II, Victor Hortaplein, 40/ 40, B-1060 Brussels, Website: www.fagg.be, e-mail: patientinfo@fagg-afmps.be. By reporting side effects you can help provide more information on the safety of this medicine. 5. HOW TO STORE TOULARYNX DEXTROMETHORPHAN FORTE. Keep this medicine out of the sight and reach of children. This medicinal product does not require any special storage conditions. Do not use Toularynx dextromethorphan forte after the expiry date which is stated on the box /the label after EXP. The first two figures indicate the month, the following two or four figures the year. The expiry date refers to the last day of that month. Toularynx dextromethorphan forte can be used until 6 months after opening. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. CONTENTS OF THE PACK AND OTHER INFORMATION. What Toularynx dextromethorphan forte contains - The active substance is dextromethorphan HBr monohydrate 3 mg/ml. - The other ingredients are sodium saccharin - sorbitol solution 70% - methyl parahydroxybenzoate - propyl parahydroxybenzoate - propylene glycol - peach flavour - sodium cyclamate - purified water. What Toularynx dextromethorphan forte looks like and contents of the pack Glass bottle of 160, 180 or 200 ml syrup with child-resistant closure of polypropylene with a polyethylene sealing disk, delivered with a measuring cup of 30 ml. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Laboratoria QUALIPHAR N.V./S.A. - Rijksweg 9-2880 Bornem - Belgium Marketing authorisation number: BE476622 Delivery mode: 160 ml: Free delivery 5/6

180 ml: On medical prescription or on written request. 200 ml: On medical prescription or on written request. This leaflet was last revised in in 07/2016. This leaflet was last approved in 08/2016. 6/6